Antiparkinson Drugs Flashcards
PD causes, risk facotrs, cardinal symptoms
95% idio patic…5% familia
Positive - age, heredity, sex, toxic
Negative - coffee, tobacco, NSAIDs
Resting tremor - pill rolling
Muscular cogwheel rigidity
Bradykineia - slowness and restricteed movement
Pathology, why survival time, and reflex vs. coluntary
Loss of dopamanergic in SN
Hallmark lewy bodies
>80% loss before symtoms
Mitchondrial dysfunction, ROS, excititoxic glutamate exposure
3-5 yrs untreated
5-10 yrs tx
Reflexes intact but voluntayr slower
PD subtypes
PD - less common…tremor main complaint…younger patients…slower
PDD - postural imabalance and gait…>70 y/o at diagnosis…akinesia, rigidity…rapid decline
Parkinsonism
Drug induced PD symptoms (due to DA antagonists like antipsychotics)
MPTP
MPTP protoxin taken up by DAergic neurons via transporter…converted to MPP+ by MAOB in astrocytes…MPP+ interferes with mitochondria…free radical uidup and death
Levodopa/L-Dopa mech and rationale
DA does not cross BBB
Prodrug has no action…crosses the BBB (unlike DA)…decarboxylated ti DA in ingrostriatal neurons…seuqestered in vesicles avaiable for release into DA deprived striatum
Dopamine creation
Tyroosine to L-dopa to dopamine
L-DOPA therapeutics
Gold standard
Efficacy decreases as disease progresses
NEver given alone
L-DOPA kinetics
AA in diet compete iwht L-DOPA for transport
Metabolized to HVA and DOPAC
1-3% into CNS
Clinical use and side effects of LDOPA
On target effects weaken and side effects strengthen as dz progresses…best early
Peripheral (because of L-DOpa to DOpa conversion)…GI distrubrances because of DOPA decarboylase in gut…tachycardia and hypotension
Central - wearing off (associated with dosing schedule), on/off(NOT associated with dosing scheudle), abnormal involuntary movements, psychotomimetic
L-Dopa interactions and contraindiciations
Vit B6 (enhances metabolism) or within 2 weeks of MAOA (hypertensive crisis)
Psychosis, glaucoma, cardiac dz, peptic ulcers, melanoma
Carbidopa
L-DOPA given with
DOes not cross BBB
Reduces Nausea and CV effects
IMproves delivery to CNS
DOpa decarbozylase inhibitors
Rationale of COMT inhibitors
Inhibiting peripheral DOPA decarbozylase upregulates COMT…converts L-DOPA to 3OMD…competes with L-DOPA for BBB transport to CNS
Entacapone, stalevo with side effects
Preferred…does not cross BBB
Entacopone + carbidopa+L-DOPA
Organge colored urine is main one
Dopamine agnosits advantage and disadvantages
Do not require nigrostriatal neurons or metabolic conversion Longer duration Selective for D2 subtype Do not conpete for trnapsort Can be monotherapeutic
Not under neuronal control
Off target